RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.54
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$38.52

13 Jun
2025

-0.330

OPEN

$38.67

-0.85%

HIGH

$38.67

681,359

LOW

$38.15

TARGET
$45.893 19.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 146.1 xxx
DPS (cps) 33.7 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.4 xxx
Dividend Yield 0.9% xxx
Div Pay Ratio(%) 23.0% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.02%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.77

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/11 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx106.0
DPS All xxxxxxxxxxxxxxx29.6
Sales/Revenue xxxxxxxxxxxxxxx7,150.0 M
Book Value Per Share xxxxxxxxxxxxxxx495.8
Net Operating Cash Flow xxxxxxxxxxxxxxx2,138.4 M
Net Profit Margin xxxxxxxxxxxxxxx21.79 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx23.10 %
Return on Invested Capital xxxxxxxxxxxxxxx18.26 %
Return on Assets xxxxxxxxxxxxxxx15.25 %
Return on Equity xxxxxxxxxxxxxxx23.10 %
Return on Total Capital xxxxxxxxxxxxxxx24.60 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,555.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx53 M
Long Term Debt xxxxxxxxxxxxxxx1,256 M
Total Debt xxxxxxxxxxxxxxx1,309 M
Goodwill - Gross xxxxxxxxxxxxxxx4,256 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx357 M
Price To Book Value xxxxxxxxxxxxxxx5.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx175.3 M
Capex % of Sales xxxxxxxxxxxxxxx2.45 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,169 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,869 M
Research & Development xxxxxxxxxxxxxxx469 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

12/05/2025

1

Buy

-

-

UBS's May 2025 A&NZ Healthcare Crowding Monitor shows investor positioning remains net long across the sector, though less so than the prior month.

The broker explains crowding can signal risk from similar investor behaviour during market events, though it does not inherently imply poor performance.

Crowding scores are calculated by UBS using ownership, stock loan, flow, and brokerage data, and provide insights into behavioural positioning risk across ANZ healthcare equities.

Notably, ResMed saw the largest shift, becoming less crowded despite a solid 3Q result and continued US tariff exemption under the Nairobi Protocol, observes the broker.

Buy. Target US$285.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

30/04/2025

2

Overweight

$40.54

5.24%

In Jarden's view, ResMed delivered a strong third quarter result, reinforcing its safe-haven status with robust top-line growth, a rising gross margin at the top end of guidance, and an accelerated share buyback program.

The broker highlights the gross margin improved by 70bps quarter-on-quarter to 59.9%, three months ahead of expectations, driven by manufacturing efficiencies, cost savings, product mix and procurement benefits.

Guidance suggests to the analysts margins could exceed 60% in the fourth quarter.

Tariff exemption confirmation under the Nairobi Protocol was a key positive, according to Jarden, ensuring ResMed’s US operations avoid new 10% tariffs, with management also emphasising the company’s growing US manufacturing presence.

The broker raises its target price to $40.54 from $39.97 and maintains an Overweight rating.

FORECAST
Jarden forecasts a full year FY25 dividend of 33.62 cents and EPS of 147.42 cents.
Jarden forecasts a full year FY26 dividend of 42.41 cents and EPS of 173.63 cents.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Rudi’s View: Amcor, GQG, IPH, Data#3 & Qualitas

Jun 12 2025 - Rudi's View
2
Rudi’s View: NextDC, QBE, Superloop & Woodside

Jun 05 2025 - Rudi's View
3
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
4
Rudi’s View: The Contrarians’ View

May 29 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – May 26, 2025

May 26 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
2
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
3
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
4
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
5
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
6
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
7
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
8
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
9
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
10
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia